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PRACTICE POINTER
Interpreting a covid-19 test result
Jessica Watson GP and National Institute for Health Research doctoral research fellow 1, Penny F
Whiting associate professor in clinical epidemiology 1, John E Brush professor of internal medicine 2
1Centre for Academic Primary Care, Bristol Medical School, University of Bristol, Bristol, UK; 2Sentara Healthcare and Eastern Virginia Medical
School, Norfolk, VA, USA
What you need to know
• Interpreting the result of a test for covid-19 depends on two things: the
accuracy of the test, and the pre-test probability or estimated risk of
disease before testing
• A positive RT-PCR test for covid-19 test has more weight than a negative
test because of the test’s high specificity but moderate sensitivity
• A single negative covid-19 test should not be used as a rule-out in
patients with strongly suggestive symptoms
• Clinicians should share information with patients about the accuracy of
covid-19 tests
Across the world there is a clamour for covid-19 testing, with
Tedros Adhanom Ghebreyesus, director general of the World
Health Organization, encouraging countries to “test, test, test.”1
The availability of the complete genome of covid-19 early in
the epidemic facilitated development of tests to detect viral
RNA.2 Multiple assays with different gene targets have been
developed using reverse transcriptase polymerase chain reaction
(RT-PCR).3 These viral RNA tests use samples usually obtained
from the respiratory tract by nasopharyngeal swab, to detect
current infections. Serology blood tests to detect antibodies
indicating past infection are being developed; these will not be
considered in depth in this article.
Testing for covid-19 enables infected individuals to be identified
and isolated to reduce spread,4 allows contact tracing for exposed
individuals,5 and provides knowledge of regional and national
rates of infection to inform public health interventions. However,
questions remain on how to apply test results to make optimal
decisions about individual patients.
Search strategy
This article was produced at speed to address an urgent need to address
uncertainties in testing for covid-19. We searched Pubmed using the terms
“covid”, “SARS-CoV-2”, “sensitivity”, “specificity”, “diagnosis”, “test”, and “PCR”,
and KSR evidence using terms for covid and test. This was supplemented by
discussion with colleagues undertaking formal systematic reviews into covid-19
diagnosis.
How accurate are test results?
No test gives a 100% accurate result; tests need to be evaluated
to determine their sensitivity and specificity, ideally by
comparison with a “gold standard.” The lack of such a clear-cut
“gold-standard” for covid-19 testing makes evaluation of test
accuracy challenging.
A systematic review of the accuracy of covid-19 tests reported
false negative rates of between 2% and 29% (equating to
sensitivity of 71-98%), based on negative RT-PCR tests which
were positive on repeat testing.6 The use of repeat RT-PCR
testing as gold standard is likely to underestimate the true rate
of false negatives, as not all patients in the included studies
received repeat testing and those with clinically diagnosed
covid-19 were not considered as actually having covid-19.6
Accuracy of viral RNA swabs in clinical practice varies
depending on the site and quality of sampling. In one study,
sensitivity of RT-PCR in 205 patients varied, at 93% for
broncho-alveolar lavage, 72% for sputum, 63% for nasal swabs,
and only 32% for throat swabs.7 Accuracy is also likely to vary
depending on stage of disease8 and degree of viral multiplication
or clearance.9 Higher sensitivities are reported depending on
which gene targets are used, and whether multiple gene tests
are used in combination.3 10 Reported accuracies are much higher
for in vitro studies, which measure performance of primers using
coronavirus cell culture in carefully controlled conditions.2
The lack of a clear-cut “gold-standard” is a challenge for
evaluating covid-19 tests; pragmatically, clinical adjudication
may be the best available “gold standard,” based on repeat
swabs, history, and contact with patients known to have
covid-19, chest radiographs, and computed tomography scans.
Inevitably this introduces some incorporation bias, where the
test being evaluated forms part of the reference standard, and
this would tend to inflate the measured sensitivity of these tests.11
Disease prevalence can also affect estimates of accuracy: tests
developed and evaluated in populations with high prevalence
(eg, secondary care) may have lower sensitivity when applied
in a lower prevalence setting (eg, primary care).11
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One community based study of 4653 close contacts of patients
with covid-19 tested RT-PCR throat swabs every 48 hours
during a 14 day quarantine period. Of 129 eventually diagnosed
with covid-19 by RT-PCR, 92 (71.3%) had a positive test on
the first throat swab, equating to a sensitivity of 71% in this
lower prevalence, community setting.12
Further evidence and independent validation of covid-19 tests
are needed.13 As current studies show marked variation and are
likely to overestimate sensitivity, we will use the lower end of
current estimates from systematic reviews,6 with the approximate
numbers of 70% for sensitivity and 95% for specificity for
illustrative purposes.
What do clinicians need to know to
understand a test result?
Sensitivity and specificity can be confusing terms that may be
misunderstood14 (see supplementary file ‘Definitions and
formulae for calculating measures of test accuracy’). Sensitivity
is the proportion of patients with disease who have a positive
test, or the true positive rate. Specificity is the proportion of
patients without disease who have a negative test, or true
negative rate. These terms describe the operating characteristics
of a test and can be used to gauge the credibility of a test result.
They can be combined to calculate likelihood ratios, which are
dimensionless numbers that indicate the strength of a positive
or negative test result.15 For calculating probabilities, a likelihood
ratio can be used as a multiplier to convert pre-test odds to
post-test odds. Positive likelihood ratios greater than 1 are
progressively stronger, with 10 representing a very strong
positive test result. Negative likelihood ratios less than 1 are
also progressively stronger, with 0.1 representing a very strong
negative test result. In the case of the nasopharyngeal swab
RNA test for covid-19, the positive likelihood ratio is about 14,
which is excellent.6 A positive covid-19 test result should be
very compelling. The negative likelihood ratio is 0.3, which is
a moderate result, but not nearly as compelling as a positive
result because of the moderate sensitivity (about 70%) of the
covid-19 test.
Interpretation of a test result depends not only on the
characteristics of the test itself but also on the pre-test probability
of disease. Clinicians use a heuristic (a learned mental short
cut) called anchoring and adjusting to settle on a pre-test
probability (called the anchor). They then adjust this probability
based on additional information. This heuristic is a useful short
cut but comes with the potential for bias. When people fail to
estimate the pre-test probability and only respond to a piece of
new information, they commit a fallacy called base-rate neglect.
Another fallacy called anchoring is failing adequately to adjust
one’s probability estimate, given the strength of new
information. Likelihood ratios can give a clinician an idea of
how much to adjust their probability estimates. Clinicians
intuitively use anchoring and adjusting thoughtfully to estimate
pre- and post-test probabilities unconsciously in everyday
clinical practice. However, faced with a new and unfamiliar
disease such as covid-19, mental short cuts can be uncertain
and unreliable and public narrative about the definitive nature
of testing can skew perceptions.
Figure 1 shows how a clinician’s thinking about a patient’s
probability should shift, based on either a positive or negative
test result for covid-19. First, the clinician should estimate a
pre-test probability, using knowledge of local rates of covid-19
infection from national16 and regional17 data and patients’
symptoms and signs,18 likelihood of alternative diagnoses, and
history of exposure to covid-19. After choosing a pre-test
probability on the x axis, one should then trace up to either the
upper curve for a positive test result or the lower curve for a
negative test result, then trace over to the y axis to read the
estimate for post-test probability. The figure shows that the shift
in the probability is asymmetric, with a positive test result
having a greater impact than a negative test result, owing to the
modest sensitivity and negative likelihood ratio of the RNA
test.
The infographic (fig 2) shows the outcomes when 100 people
with a pre-test probability of 80% are tested for covid-19 using
natural frequencies, which are generally easier to understand.
Online calculators are available which allow clinicians to adjust
pre-test probability, sensitivity, and specificity to estimate
post-test probability19
What else should clinicians consider
when interpreting test results?
A single negative test result may not be
informative if the pre-test probability is high
A 52 year old general practitioner in London develops a cough,
intermittent fever, and malaise. On day 2 of his illness he
receives a nasopharyngeal swab test for covid-19, which is
reported as negative. His cough and low-grade fever persist
but he feels systemically well enough to return to work. What
should he do?
Pre-test probability is high in someone with typical symptoms
of covid-19, an occupational risk of exposure, and working in
a high prevalence region, and negative test results can therefore
be misleading. Table 1 shows that for a pre-test probability of
90%, someone with a negative test has a 74% chance of having
covid-19; with two negative tests this risk is still around 47%.
If this doctor were to return to work and subsequently the test
was confirmed as a false negative, then the decision to work
would potentially have significant consequences for his patients,
colleagues, and everyone with whom he came into contact. It
is therefore safest for this GP with strongly suggestive symptoms
to self-isolate in line with guidelines for covid-19, even though
his test results are negative. This case illustrates the fallacy of
base-rate neglect; it can be tempting to trust the results of an
“objective” test more than one’s own “subjective” clinical
judgement. In general, during this pandemic, pre-test
probabilities of covid-19 will be high, particularly in high
prevalence secondary care settings.
A possible alternative diagnosis will reduce
the pre-test probability
A 73 year old woman with severe chronic obstructive pulmonary
disease (COPD) and a chronic cough develops acute shortness
of breath and slight worsening of her non-productive cough.
She reports no fever, has no known exposure to covid-19, and
no recent travel. She presents to an emergency department
where she is acutely short of breath. A chest radiograph shows
possible infiltrates in the right upper and middle lung fields.
She is admitted and placed in isolation on droplet precautions.
She requires intubation for worsening respiratory distress.
Initial nasopharyngeal covid-19 testing is negative. Should she
remain in isolation on droplet precautions?
This patient has an alternative possible diagnosis:
community-acquired pneumonia. Given her lack of other risk
factors or clinical symptoms, and chest radiography findings
we therefore estimate her pre-test probability at about 50%. One
negative test reduces this risk to 24%, the patient therefore has
an additional independently sampled nasopharyngeal swab RNA
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test which was negative, giving a post-test probability after two
negative tests of less than 10%. She is treated with antibiotics
and continues to recover.
What are the implications for practice and
policy?
While positive tests for covid-19 are clinically useful, negative
tests need to be interpreted with caution, taking into account
the pre-test probability of disease. This has important
implications for clinicians interpreting tests and policymakers
designing diagnostic algorithms for covid-19. The Chinese
handbook of covid-19 prevention and treatment states “if the
nucleic acid test is negative at the beginning, samples should
continue to be collected and tested on subsequent days.”20 False
negatives carry substantial risks; patients may be moved into
non-covid-19 wards leading to spread of hospital acquired
covid-19 infection,21 carers could spread infection to vulnerable
dependents, and healthcare workers risk spreading covid-19 to
multiple vulnerable individuals. Clear evidence-based guidelines
on repeat testing are needed, to reduce the risk of false negatives.
Clinicians should ensure that patients are counselled about the
limitations of tests (box 1). Patients with a single negative test
but strongly suggestive symptoms of covid-19 should be advised
to self-isolate in keeping with guidelines for suspected covid-19.
Box 1: Possible phrases for explaining covid-19 testing to
patients
• No test is 100% accurate
• If your swab test comes back positive for covid-19 then we can be very
confident that you do have covid-19
• However, people with covid-19 can be missed by these swab tests. If
you have strong symptoms of covid-19, it is safest to self-isolate, even
if the swab test does not show covid-19
What is the role of serology tests?
Serology tests, which detect immunoglobulins including IgG
and IgM, are under development,22-24 with the aim of detecting
individuals who have had previous infection and therefore
theoretically developed immunity. The time course and accuracy
of serology tests are still under investigation, but the same
principles of incorporating the test result with the clinical
impression applies. False positive serology tests could cause
false reassurance, behaviour change, and disease spread. If
suitable accuracy can be established, the benefits of these
antibody tests include establishing when healthcare workers are
immune, helping to inform decisions about the lifting of
lockdowns, and allowing the population to return to work.25
The WHO message “test, test, test”1 is important from a
population perspective; low sensitivity can be accounted for
when assessing burden of disease. However RT-PCR tests have
limitations when used to guide decision making for individual
patients. Positive tests can be useful to “rule-in” covid-19, a
negative swab test cannot be considered definitive for “ruling
out.”
How patients were involved in the creation of this article
Patients with covid-19 or possible covid-19 were not involved in the writing of
this paper for practical reasons
Education into practice
What is the protocol for covid-19 testing in your organisation?
How do you explain covid-19 test results to patients?
Reflect on a recent clinical case of suspected covid-19—what was your
estimated pre-test probability? How did this alter with the results of tests?
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Table
Table 1| Pre- and post- test probabilities for covid-19 RT-PCR tests, calculations based on a sensitivity of 70% and specificity of 95%
Post-test probability positive testPost-test probability, two independently negative testsPost-test probability, negative testPre-test probability
420.51.65
712515
8231025
9392450
98234975
99477490
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Figures
Fig 1 Leaf plot for covid-19 RT-PCR tests based on a sensitivity of 70% and specificity of 95%. The x axis gives the estimated
pre-test probability of covid-19 based on the clinical details. The post-test probability is obtained by tracing up and
across to the y axis from the lower curve for a negative test, or to the upper curve for a positive test result. The dashed
lines illustrate pre-test probability of 90% (clinical case 1) and 50% (clinical case 2)
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Fig 2 Infographic showing outcomes of 100 people who are tested for covid-19
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